THE USE OF FACTOR-VIII INHIBITOR BY-PASSING ACTIVITY (FEIBA IMMUNO) PRODUCT FOR TREATMENT OF BLEEDING EPISODES IN HEMOPHILIACS WITH INHIBITORS

  • 1 January 1983
    • journal article
    • research article
    • Vol. 61  (1) , 36-40
Abstract
FEIBA (factor 8 inhibitor bypassing activity) Immuno was used to achieve hemostasis in 46 patients with factor VIII inhibitors with titers > 4 Bethesda units and 3 patients with factor IX inhibitors. Bleeding episodes (165) were treated with 50-70 U/kg; 102 of these episodes occurred in joints, 20 in mucous membranes, 33 muscle and soft tissue and 10 were emergency episodes including 3 CNS and 4 surgical procedures. The bleeding episodes were controlled in 93% of the cases, while 7% were not controlled: 36% were controlled by 1 infusion in 12 h, 42% with .gtoreq. 1 infusions in 36 h, and 14% in > 36 h. There were no serious side effects, and while the inhibitor titer rose in 10 of the patients, the product continued to be efficacious.